Lamotrigine
| Evidence Level: L2 | Predicted Indications: 9 |
Table of Contents
Lamotrigine: From Epilepsy to Trigeminal Neuralgia
One-Sentence Summary
Lamotrigine is an established antiepileptic drug (AED), also widely used as a mood stabiliser in bipolar disorder. Among the nine TxGNN candidate indications supplied for this drug, the TxGNN model’s top-ranked candidate (“trigeminal nerve neoplasm”) is flagged in its own rationale as an anatomical-proximity artefact with no mechanistic basis, so this report instead focuses on the strongest supported candidate — Trigeminal Neuralgia — which is backed by 4 clinical trials (including one completed Phase 2/3 RCT) and 19 publications, including a European Academy of Neurology guideline.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified in this evidence pack (Lamotrigine is licensed internationally as an antiepileptic/mood-stabilising agent; no local licence record supplied) |
| Predicted New Indication | Trigeminal Neuralgia |
| TxGNN Prediction Score | 99.89% |
| Evidence Level | L2 |
| UK Market Status | Not marketed (no licences on record for this jurisdiction) |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Proceed with Guardrails |
Note on candidate selection: The evidence pack’s highest-scoring TxGNN prediction (rank 1, “trigeminal nerve neoplasm”, score 99.97%) was excluded from this report. Its own rationale states there is “no plausible mechanistic link” — Lamotrigine has no known antineoplastic activity, and the literature behind it merely describes tumours that can cause trigeminal neuralgia, not evidence that Lamotrigine treats tumours. This is a clear case of the model confusing indications sharing an anatomical term. Trigeminal neuralgia (rank 2) is the most credible candidate in the set.
Why is This Prediction Reasonable?
Detailed DrugBank mechanism-of-action data was not available for this record (flagged as a data gap). However, the evidence pack’s own repurposing rationale confirms that Lamotrigine is a voltage-gated sodium channel blocker, reducing pathological high-frequency neuronal firing. This is the same fundamental mechanism as carbamazepine and oxcarbazepine — the current first-line drugs for trigeminal neuralgia — providing a coherent pharmacological rationale for the prediction.
Trigeminal neuralgia is a neuropathic facial pain syndrome driven by aberrant, high-frequency discharges in the trigeminal nerve, typically from vascular compression and focal demyelination. Because Lamotrigine’s antiepileptic action works by dampening exactly this type of abnormal neuronal excitability, its use in trigeminal neuralgia is a logical extension of its established antiepileptic pharmacology rather than a novel mechanistic hypothesis — this is supported directly by head-to-head clinical data against carbamazepine (see NCT00913107 below).
The wider set of TxGNN predictions for this drug (startle epilepsy, audiogenic seizures, reading seizures, etc.) reflects a consistent underlying signal: Lamotrigine’s broad-spectrum antiepileptic activity extending to reflex/triggered seizure syndromes. These are noted here for completeness but carry weaker (L4–L5) evidence than trigeminal neuralgia and are not the focus of this report.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT00913107 | Phase 2/3 | Completed | 21 | Direct comparison of Lamotrigine versus carbamazepine for efficacy and safety in trigeminal neuralgia — the strongest direct evidence in this evidence pack. |
| NCT00203229 | Not specified | Completed | 20 | Double-blind, placebo-controlled add-on study of Lamotrigine (Lamictal) in patients with trigeminal neuralgia (tic douloureux). |
| NCT00243152 | Not specified | Completed | 6 | fMRI evaluation of Lamotrigine’s effect on neuropathic facial pain/neuralgia — mechanistic, not an efficacy endpoint; very small sample. |
| NCT04996199 | Phase 4 | Unknown | 132 | Compares carbamazepine versus oxcarbazepine for trigeminal neuralgia; does not include Lamotrigine directly, so relevance is low. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 21621166 | 2011 | Clinical Study | Journal of the Chinese Medical Association | Direct comparison of Lamotrigine and carbamazepine for efficacy and tolerability in trigeminal neuralgia patients (published counterpart of NCT00913107). |
| 30860637 | 2019 | Guideline | European Journal of Neurology | European Academy of Neurology guideline on trigeminal neuralgia management. |
| 37892981 | 2023 | Systematic Review | Biomedicines | Umbrella review of drugs used for trigeminal neuralgia, evaluating efficacy and side effects. |
| 34108244 | 2021 | Review | Practical Neurology | Practical guide to trigeminal neuralgia diagnosis and management. |
| 38870050 | 2024 | Review | Expert Review of Neurotherapeutics | Update on pharmacotherapy for trigeminal neuralgia, discussing older and newer anticonvulsant options. |
| 31908187 | 2020 | Review | Molecular Pain | Overview of trigeminal neuralgia pathophysiology and pharmacological treatments. |
| 30081317 | 2018 | Case Report | Multiple Sclerosis and Related Disorders | Refractory trigeminal neuralgia successfully treated with combination therapy (Pregabalin plus Lamotrigine). |
| 25299564 | 2014 | Review | BMJ Clinical Evidence | Clinical evidence review of trigeminal neuralgia presentation and management. |
| 19445753 | 2009 | Review | BMJ Clinical Evidence | Earlier BMJ Clinical Evidence review of trigeminal neuralgia. |
| 29114270 | 2017 | Review | Asian Journal of Neurosurgery | General review of trigeminal neuralgia presentation and mechanisms. |
UK Market Information
No marketing authorisation is currently on record for Lamotrigine in this jurisdiction (market status: Not marketed, 0 licences). No product name, dosage form, or approved indication text is available in the evidence pack for this jurisdiction.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
(Key warnings, contraindications, and drug–drug interaction data were flagged as data gaps in this evidence pack — notably local product labelling (TFDA/SmPC equivalent), listed as a Blocking gap that prevents safety pre-screening.)
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: A completed Phase 2/3 RCT directly comparing Lamotrigine to carbamazepine (the current standard of care), supported by an additional double-blind add-on trial and an EAN clinical guideline, gives a credible but limited evidence base (small sample sizes, n=20–21) for repurposing Lamotrigine in trigeminal neuralgia.
To proceed, the following is needed:
- Local product labelling / SmPC data (warnings, contraindications, DDI) — currently a Blocking data gap
- Full DrugBank mechanism-of-action record — currently a High-severity data gap
- Confirmation of marketing authorisation status in this jurisdiction, since none is currently on record
- A larger, adequately powered confirmatory RCT, given the largest existing trial enrolled only 21 patients
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.